Biomira News

Oncothyreon Inc. today announced that the first patient has been treated in a Phase 1b clinical trial of PX-12 in patients with advanced metastatic cancer.

Oncothyreon Inc. today announced that Daniel K. Spiegelman and Stephen K. Burley, M.D., D.Phil. have joined its board of directors for three-year terms.

Oncothyreon Inc. today announced the presentation of two-year survival data from a Phase 1/2 multicenter study of Stimuvax in patients with unresectable stage III non-small cell lung cancer.

“PX-866 is a potent inhibitor of phosphatidylinositol-3-kinase that has demonstrated preclinical anti-tumor activity in models of human ovarian cancer, lung cancer and intracranial glioblastoma”

Oncothyreon Inc. recently announced that it has filed an investigational new drug application with the U.S. Food and Drug Administration for PX-866, a small molecule phosphatidylinositol-3-kinase inhibitor for ... via Pharmaceutical Online

Oncothyreon Inc. announced today that data from preclinical studies of PX-478, pharmacodynamic studies of PX-12 and preclinical studies of PX-866 will be presented at the Annual Meeting of the American ... via Canada NewsWire

“We expect to file an Investigational New Drug Application for PX-866 in the coming quarter and to initiate a Phase 1 trial soon thereafter.”

Oncothyreon Inc. today announced that the U.S. Patent and Trademark office has issued a patent for PX-867, a small molecule compound currently in preclinical development. via Canada NewsWire

Oncothyreon Inc. , a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief ... via Canada NewsWire

BELLEVUE, WA, March 10 /CNW/ - Oncothyreon Inc. today reported financial results for the year and quarter ended December 31, 2007. via Canada NewsWire

Oncothyreon Inc. , a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its fourth quarter and full ... via CNW Group

“Today represents a major milestone in our plan for Oncothyreon to become a leading developer of innovative therapeutic products in oncology”

Oncothyreon Inc. today announced that its common stock will begin trading on the Nasdaq Global Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY at the opening of trading ... via Canada NewsWire

Puget Sound Business Journal A Canadian biotech company called Biomira Inc. said it's moving from Edmonton, Alberta, to the Seattle area and is changing its name to Oncothyreon Inc. via Bizjournals

Biomira Inc. has announced that the Alberta Court of Queen's Bench issued a Final Order approving the plan of arrangement under which the Company will move to the United States and change its name to ... via Medical News

Canadian cancer-treatment developer Biomira Inc said on Tuesday that its shareholders have approved a plan to rename the company and move it to the United States. via Sympatico Finance

Daimler, Ford successful suitors in sale of division Act I: Buy low, cell high * Action: Up five per cent or $0.23 in a month * 52-Week High/Low: $9.15/4.32 The rubber has finally hit the road. via Business Edge

Biomira Inc. today announced that on November 2, 2007, it received a letter from The Nasdaq Stock Market, Inc. via Canada NewsWire

“Hypoxia is a feature of many solid tumors and HIF-1 alpha is the tumor's primary survival response to this stress”

Biomira Inc. announced today that preclinical data for its targeted anti-cancer drug candidates PX-478 and PX-866 were presented in a poster session yesterday at the AACR-NCI-EORTC International Conference on ... via Canada NewsWire

Biomira to change name as part of reincorporation plan SAN FRANCISCO -- Biomira Inc. via WBAV-FM Charlotte

Biomira Inc. said Thursday it plans to change its name as part of its reincorporation in the U.S. The Edmonton, Alberta-based biotechnology company said it will change its name to Oncothyreon Inc. via Market Watch

By using this site, you agree to the Terms of Service and Privacy Policy . BIOM Stock Quote - Biomira Inc Stock Quote - BIOM Quote - BIOM Stock Price Intraday data provided by Comstock , a division of ... via Market Watch

“We are a different company today than we were just twelve months ago, and our decision to change our name to Oncothyreon reflects that transformation. Oncothyreon is derived from the Greek words for "tumor”

Biomira Inc. today announced that, as part of the Company's previously announced plan to reincorporate in the United States, it intends to change its name to Oncothyreon Inc. via Canada NewsWire